Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Guggenheim Healthcare Talks 2022 Oncology Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers

Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the 4th Annual Evercore ISI HealthCONx Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q3 2021 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming Stifel 2021 Virtual Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline

Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time

Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021

Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session

Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs

Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Revolution Medicines, Inc. (RVMD) CEO Dr. Mark Goldsmith on Q2 2021 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates

Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 30.43% year over year to ($0.60), which missed the estimate of ($0.56).

Revolution Medicines: Q2 Earnings Insights

Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors;  Scientific Publication is First to Demonstrate Anti-Drug Resistance Features

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (RVMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development

News for Revolution Medicines Stock (RVMD)